EP4200285A1 - New isobutyryamide derivatives, cosmetic and/or dermatological preparations containing said compounds, and their use for the prophylaxis and treatment of sensible, in particular inflamed skin or inflammatory skin conditions - Google Patents
New isobutyryamide derivatives, cosmetic and/or dermatological preparations containing said compounds, and their use for the prophylaxis and treatment of sensible, in particular inflamed skin or inflammatory skin conditionsInfo
- Publication number
- EP4200285A1 EP4200285A1 EP21762623.3A EP21762623A EP4200285A1 EP 4200285 A1 EP4200285 A1 EP 4200285A1 EP 21762623 A EP21762623 A EP 21762623A EP 4200285 A1 EP4200285 A1 EP 4200285A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- connection
- cosmetic
- isobutyramides
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 38
- 238000011282 treatment Methods 0.000 title claims description 13
- 238000011321 prophylaxis Methods 0.000 title claims description 11
- 230000002757 inflammatory effect Effects 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title description 3
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical class CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000002374 sebum Anatomy 0.000 claims description 31
- 206010000496 acne Diseases 0.000 claims description 30
- 210000004209 hair Anatomy 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 11
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000001840 Dandruff Diseases 0.000 claims description 8
- 230000007803 itching Effects 0.000 claims description 8
- 230000037307 sensitive skin Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 229940047889 isobutyramide Drugs 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 67
- 210000001732 sebaceous gland Anatomy 0.000 description 21
- 239000000126 substance Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 206010039792 Seborrhoea Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 9
- 208000008742 seborrheic dermatitis Diseases 0.000 description 9
- 239000000344 soap Substances 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241001303601 Rosacea Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- SZGGFZROULDDBT-UHFFFAOYSA-N N-[4-(2,4-dihydroxy-3-methylphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound CC(C)C(NC1=NC(C(C=CC(O)=C2C)=C2O)=CS1)=O SZGGFZROULDDBT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 239000008233 hard water Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 description 1
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 description 1
- 206010068773 Mechanical urticaria Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JUHBYQVPEUGWBO-UHFFFAOYSA-N N-[4-(2,4-dimethoxyphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound COC1=CC(OC)=CC=C1C1=CSC(NC(=O)C(C)C)=N1 JUHBYQVPEUGWBO-UHFFFAOYSA-N 0.000 description 1
- OQYBNVKSJCRWOU-UHFFFAOYSA-N N-[4-(2-hydroxy-4-methoxyphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound CC(C)C(NC1=NC(C(C=CC(OC)=C2)=C2O)=CS1)=O OQYBNVKSJCRWOU-UHFFFAOYSA-N 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000000409 dermatographia Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000020157 familial dermatographia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- -1 hydroxy-methoxy-phenylthiazole isobutyramide Chemical compound 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001354 painful effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000003779 seborrheic infantile dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention relates in particular to N-(4-(2,4-dihydroxy- 3-methylphenyl) thiazole-2-yl) isobutyramide and hydroxy-methoxy-phenylthiazole isobutyramide, but also their derivatives, cosmetic and / or dermatological preparations containing them, and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions in human skin. Changes associated with the aging process, but also other intrinsic and extrinsic factors (e.g.
- skin irritation is to be understood as meaning any change in the skin that triggers sensory discomfort in humans or animals and/or is characterized by a dry, reddened and/or inflamed complexion.
- sensory discomfort also includes conditions such as itching or pain.
- skin irritation can include phenomenologically different skin conditions: Sensitive skin, sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
- Sensitive skin sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
- the problem of "sensitive skin” affects a growing number of adults and children. It is now assumed that up to 50% of the population has sensitive skin (L. Misery et al., Ann. Dermatol. Venereol.2005, 132, 425-4
- Typical disturbing phenomena associated with the terms "stinging” or “sensitive skin” are skin reddening, tingling, tingling, tightening and burning of the skin and itching. They can be caused by stimulating environmental conditions such as B. massage, surfactants, exposure to other chemical substances such. B. lactic acid, weather influences such as heat, cold, drought, but also damp heat, thermal radiation and UV radiation, z. B. the sun, or psychological stress.
- “Sensitive” scalps are also characterized by skin redness, tingling, tingling, burning and itching. Triggers are, for example, soap, shampoo or other hair care products, surfactants, hard water with a high concentration of lime and/or mechanical stress. Erythema and hyperseborrhoea (excessive production of sebum) of the scalp and dandruff are often associated with the phenomena described.
- Atopy a familial hypersensitivity of the skin and mucous membranes to environmental substances, with an increased willingness to react to substances from the natural environment. to develop. Atopy is thought to be genetic. Atopy can manifest itself as atopic dermatitis. The skin barrier is damaged, the skin is often inflamed and itchy.
- the erythematous effect of the ultraviolet part of solar radiation or artificial radiation on the skin is well known. While rays with a wavelength shorter than 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns. Erythematous skin manifestations also occur as side effects of certain skin diseases or irregularities, for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
- certain skin diseases or irregularities for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
- Rosacea is a special form of reddening of the skin. Anti-inflammatory preparations can therefore also are used to advantage in general, disease-related reddening of the skin and in particular rosacea to subside, to suppress them over a longer period of time and to largely prevent their recurrence.
- Anti-inflammatory agents can therefore also help to reduce the consequences of an insect bite, such as reddening, wheal formation, itching and painful swelling of the skin, suppress them over a longer period of time and prevent them from reoccurring.
- Erythemas also occur more frequently in the diaper area of small children, all the more so in infants (diaper dematitis). Incontinence, a condition that occurs more frequently in older people, is often associated with erythema and reddening of the skin as a result of constant exposure to moisture and irritants (incontinence dermatitis).
- the substances used in cosmetic and/or pharmaceutical products are - toxicologically harmless, - well tolerated by the skin, - stable (in particular in conventional cosmetic and/or pharmaceutical formulations), - preferably faintly odorous or (largely) odorless, - preferably colorless and non-discolouring, and - be inexpensive to produce (ie using standard processes and/or starting from standard precursors).
- an anti-inflammatory active ingredient which preferably fulfills one or more of the aforementioned secondary conditions and particularly preferably all of the aforementioned conditions.
- the present invention relates to the use of topical preparations for removing sebum from the skin, in particular for removing and clearing comedones, for preventing the formation of comedones, for the prophylaxis and treatment of mild forms of acne and for the prophylaxis and control of seborrhea.
- Sebum is the secretion of the sebaceous gland. Sebaceous glands are bulges in the follicular epithelium and are therefore part of the follicle, with which they form a functional unit. They are holocrine glands, which means that most of the gland cell is converted into the secretion sebum. The cells of the sebaceous gland, which are constantly renewed from below, become fatty and disintegrate, and the skin sebum thus formed is emptied through the follicle openings onto the skin's surface.
- the sebum consists of mono -, di- and triglycerides (C 10 -C 18 ), waxes (C 16 -C 26 ), wax esters (C 28 -C 38 ), normal saturated fatty acids (C 10 -C 18 ), branched chain saturated fatty acids (C 11 - C 18 ), polybranched saturated fatty acids (C 13 -C 18 ), monounsaturated fatty acids (C 11 - C 18 ), polyunsaturated fatty acids (C 13 , C 15 -C 17 ), sterols (cholesterol, 7-dehydrocholesterol, 7-hydroxycholesterol), branched and unbranched hydrocarbons (C 30 -C 40 ), squalene and phospholipid
- the lipids of the sebaceous glands form the so-called hydro-lipid film of the skin.
- This surface film is an emulsion, which can be a water-in-oil or an oil-in-water emulsion. It has the function of keeping the skin's surface supple and regulating the water content of the deeper skin layers.
- the sebum When the sebum is well hydrated, the water content is at least 10 to 20% by weight and the sebum is hydrophilic. If the hydrophilic-lipophilic balance of the surface film is no longer given and the water content falls, the sebum changes and becomes hydrophobic. The flow of sebum from the sebaceous gland and follicle is impeded. The sebum accumulates in the follicle openings, which can then lead to comedones and inflammation of the follicles.
- comedones can have various causes. For example: external influences such as incorrect cleaning habits and incorrect care, comedogenic substances in cosmetics, weather influences, alkaline soaps, harsh detergents. Increased sebum secretion and the formation of comedones can also develop as a result of genetic factors and hormonal influences. Here, too, comedones, inflammation, pre-acne and acne with their after-effects can be the result.
- soaps have the disadvantage that the water-insoluble calcium and magnesium salts of the higher fatty acids that form when the soaps are used in hard water form slimy deposits on the skin. If it is difficult to rinse off, these deposits remain on the skin longer, clog the follicle openings and can lead to the formation of comedones. For this reason, syndets (i.e. non-soap tensides) in the form of cleansing creams or cleansing lotions are predominantly used for skin cleansing. Although these syndets do not form lime soaps, treatment with highly surface-active agents has a stronger degreasing and drying effect on the skin than soap.
- Seborrhea is a predisposition to increased function of the sebaceous glands. Both scalp and facial skin appear greasy. The composition of seborrhoeic sebum is different from that of normal sebum. There are 3 stages of seborrhoea development:
- the excessive secretion of the sebaceous glands can be triggered, among other things, by androgenetic disorders and has an aesthetic disadvantage on the overall appearance of the hair. This disorder can also be the cause of hair loss that occurs.
- the precursor to each is the seborrhoeic condition of the scalp. Vegetative disorders and improper care can worsen the complexion and hair condition. Even with seborrhea, the hair itself can be dry due to disturbances in the keratin structure. Dry, damaged hair is often caused by external stress such. B. sun or chemical treatments. Blow-drying that is too hot or not properly caring for damaged hair can lead to damage.
- Greasy hair has very annoying effects.
- the hair becomes stringy again a short time after washing and the hairstyle does not last.
- Greasy hair and dandruff are among the most common hair problems. These anomalies are due to a disturbance in the activity of the sebaceous glands. If the sebaceous glands are overactive, we speak of seborrhea. There are two forms to be distinguished: the oily form (seborrhea oleosa) and the dry form (seborrhea sicca).
- the treatment of seborrhea includes, first of all, regular and thorough washing of the head with special shampoos, which can be carried out as often as seems necessary.
- the wash should be combined with a massage in the connective tissue, because this empties the sebaceous glands more, which delays the subsequent greasing.
- the object of the present invention is to provide a preparation that does not have the disadvantages of the known and previously used agents, which simultaneously has a sebum-dissolving, fat-regulating and caring effect, removes existing comedones without irritation, and degreases and dehydrates the skin effectively prevents the formation of comedones and the development of acne cosmetics, as well as improves existing acne and cares for the skin in the same way.
- Isobutyramides of the general formula where n: means that 1 to 5 identical and/or different substituents R 1 are present can, where the single or multiple substituents R 1 : independently of one another can mean: OH, CH 3 , O-CH 3 , O- (CO) -CH 3 (acetyl), wherein
- R 2 H or a C 1 - C 4 - alkyl chain
- R 3 can be H or CH 3 but excludes the isobutyramide of the structure.
- the isobutyramides according to the invention are excellent active ingredients for the prophylaxis and treatment of sensitive skin, itching and inflammatory phenomena in human skin.
- the active ingredients used according to the invention prevent the formation of seborrheic phenomena, particularly greasy hair but also dandruff, and eliminate existing seborrheic phenomena, particularly greasy hair but also dandruff.
- the present invention ensures very good skin care, combined with efficient removal of excess skin sebum.
- a method for combating impure skin, acne, or seborrheic phenomena, in particular greasy hair and/or dandruff is characterized in that the active ingredients used according to the invention are in a suitable cosmetic or dermatological vehicle with which the increased sebum production is affected Area to be contacted.
- the prior art did not provide the slightest indication of the use according to the invention as an antiseborrheic principle of action.
- a further preferred embodiment of the present invention are therefore formulations to be used against dandruff, for example anti-dandruff shampoos.
- EP 3 176 156 A1 describes similar isobutyramides, but the substances according to the invention are not specifically disclosed in this document.
- EP 3 176 156 A1 is the reduction in skin pigmentation.
- this effect does not occur with the (here) isobutyramides according to the invention and would also be undesirable according to the invention.
- Cosmetic or dermatological preparations according to the invention preferably contain 0.000001 to 10% by weight, particularly preferably 0.0001 to 3% by weight and very particularly preferably 0.001 to 1% by weight of isobutyramides, based on the total weight of the preparations.
- connection 1 isobutyramides for the purposes of the present invention.
- connection 9 connection 10
- the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention takes place in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
- the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be present in various forms. So you can e.g. a solution, an emulsion of the water-in-oil (W/O) or oil-in-water (O/W) type, or a multiple emulsion, for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O), a hydrodispersion or lipodispersion, a Pickering emulsion, a gel, a solid stick or an aerosol.
- W/O water-in-oil
- O/W oil-in-water
- a hydrodispersion or lipodispersion for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O)
- a hydrodispersion or lipodispersion for example of the water
- Emulsions according to the invention for the purposes of the present invention are advantageous and contain z.
- auxiliaries and additives include, for example, consistency enhancers, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, sunscreens, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances, etc.
- Medicinal topical compositions within the meaning of the present invention usually contain one or more medicaments in an effective concentration.
- cosmetic or topical dermatological compositions according to the present invention can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day or night cream, etc. It is optionally possible and advantageous to use the compositions according to the invention as a basis to use for pharmaceutical formulations.
- the cosmetic and dermatological preparations according to the invention are applied to the skin and/or the hair in sufficient amounts in the manner customary for cosmetics. upset by the crowd.
- sunscreen preparations which are in the form of a sunscreen are particularly preferred.
- these can additionally contain at least one further UVA filter and/or at least one further UVB filter and/or at least one inorganic pigment, preferably an inorganic micropigment.
- the cosmetic and dermatological preparations can contain cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- An additional content of customary antioxidants is generally preferred. According to the invention, all antioxidants that are suitable or customary for cosmetic and/or dermatological applications can be used as favorable antioxidants.
- the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 -
- the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
- Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
- Fats, waxes and other natural and synthetic fatty substances preferably esters of fatty alcohols with alcohols with a low carbon number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids;
- Alcohols, diols or polyols with a low carbon number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
- mixtures of the aforementioned solvents are used.
- water can also be an additional component.
- the cosmetic or dermatological preparation according to the present invention is a solution or emulsion or dispersion
- the following solvents can be used: water or aqueous solutions oils such as triglycerides of capric or caprylic acid, but preferably castor oil; - fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols with a low carbon number, e.g.
- mixtures of the aforementioned solvents are used.
- water can also be an additional component.
- suitable propellants for cosmetic and/or dermatological preparations that can be sprayed from aerosol containers are the customary, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Compressed air is also advantageous to use.
- Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents customarily used for this purpose, preferably water, also organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, Hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose or inorganic thickeners, e.g. B. aluminum miniumsilicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
- the thickening agent is contained in the gel, for example, in an amount of between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
- the light protection formulations can advantageously contain further substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
- Leukotrienes which also promote inflammation, can also be formed from arachidonic acid in the skin by migrating neutrophilic granulocytes. Therefore, a reduction in leukotrienes, especially LTB 4 , is recommended for efficient effectiveness.
- Figure 2 demonstrates the reduction of Ca ionophore-stimulated LTB 4
- Granulocytes are the first immune cells to migrate into the skin after an inflammatory stimulus. Although the "oxidative burst" of the granulocytes is very important for the defense against infection, an excessive burst in the tissue can cause major collateral damage. In the case of severe inflammation, it may therefore be advisable to dampen this reaction with anti-inflammatory substances.
- Fig. 3 demonstrates the reduction of the "oxidative burst" of fMLP-stimulated neutrophils
- step 03 Compound 2: N-(4-(2,4-bis(methoxy)phenyl)thiazol-2-yl)isobutyramide Step 01 step 02 step 03 Connections 12 and 13 step 01 step 02 or
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
Abstract
New isobutyramides.
Description
Beschreibung Neue Isobutyramidderivate, kosmetische und/oder dermatologischen Zubereitungen, solche Verbindungen enthaltend, sowie deren Verwendung zur Prophylaxe vor und Behandlung von sensibler, insbesondere entzündeter Haut bzw. entzündlichen Hautzuständen Die vorliegende Erfindung betrifft insbesondere N-(4-(2,4-Dihydroxy-3-methylphenyl)th-iazol- 2-yl)-isobutyramid und Hydroxy-Methoxy-Phenylthiazol-Isobutyramid, aber auch deren Derivate, kosmetische und/oder dermatologische Zubereitungen, diese enthaltend, sowie deren Verwendung zur Prophylaxe vor und Behandlung von sensibler, insbesondere entzündeter Haut bzw. entzündlichen Hautzuständen in der menschlichen Haut. Mit dem Alterungsprozess verbundene Veränderungen, aber auch andere intrinsische und extrinsische Faktoren (z.B. Schädigung der Hautbarriere, Einwirkung von UV-Licht, irritierenden oder allergieauslösenden Substanzen, mechanische Einwirkung z.B. durch Rasur) können zu einer Hautirritation führen. Unter Hautirritation ist im Zusammenhang mit dieser Anmeldung jede Veränderung der Haut zu verstehen, die bei Mensch oder Tier sensorisches Missempfinden auslöst oder/und durch ein trockenes, gerötetes und/oder entzündetes Hautbild geprägt ist. Dabei umfasst der Begriff sensorisches Missempfinden selbstverständlich auch Zustände wie Jucken oder Schmerz. Hautirritation kann insbesondere phänomenologisch verschiedene Hautzustände umfassen: Sensible Haut, empfindliche Haut inklusive empfindlicher Kopfhaut, verletzliche Haut, trockene Haut, atopische und psoriatische Haut, irritierte Haut, Rosacea, entzündete Haut, sowie Hautveränderungen bei Diabetes mellitus, die sich im jeweils höheren Schweregrad in einer Hautrötung, dem sogenannten Erythem äußert. Das Problem "sensible Haut" betrifft eine wachsende Anzahl Erwachsener und Kinder. Man geht inzwischen davon aus, dass bis zu 50 % der Bevölkerung eine sensible Haut haben (L. Misery et al., Ann. Dermatol. Venereol.2005, 132, 425-429). Mit sensibler Haut bezeichnet
xan eine Haut mit einer erniedrigten Reizschwelle für Irritantien, wie hyperreaktive und intolerante, aber auch atopische Haut. Bei Menschen mit sensibler, empfindlicher oder verletzlicher Haut kann ein mit "Stinging" (engl. "to sting" = verletzen, brennen, schmerzen) bezeichnetes Phänomen beobachtet werden. Typische, mit den Begriffen "Stinging" oder "empfindlicher Haut" in Verbindung gebrachte, störende Phänomene sind Hautrötung, Kribbeln, Prickeln, Spannen und Brennen der Haut und Juckreiz. Sie können durch stimulierende Umgebungsbedingungen wie z. B. Massage, Tensideinwirkung, Einwirkung weiterer chemischer Substanzen wie z. B. Milchsäure, Wettereinfluss wie Wärme, Kälte, Trockenheit, aber auch feuchte Wärme, Wärmestrahlung und UV-Strahlung, z. B. der Sonne, oder psychologischen Stress hervorgerufen werden. Description of new isobutyramide derivatives, cosmetic and/or dermatological preparations containing such compounds and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions. The present invention relates in particular to N-(4-(2,4-dihydroxy- 3-methylphenyl) thiazole-2-yl) isobutyramide and hydroxy-methoxy-phenylthiazole isobutyramide, but also their derivatives, cosmetic and / or dermatological preparations containing them, and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions in human skin. Changes associated with the aging process, but also other intrinsic and extrinsic factors (e.g. damage to the skin barrier, exposure to UV light, irritating or allergenic substances, mechanical impact, e.g. from shaving) can lead to skin irritation. In the context of this application, skin irritation is to be understood as meaning any change in the skin that triggers sensory discomfort in humans or animals and/or is characterized by a dry, reddened and/or inflamed complexion. Of course, the term sensory discomfort also includes conditions such as itching or pain. In particular, skin irritation can include phenomenologically different skin conditions: Sensitive skin, sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema. The problem of "sensitive skin" affects a growing number of adults and children. It is now assumed that up to 50% of the population has sensitive skin (L. Misery et al., Ann. Dermatol. Venereol.2005, 132, 425-429). Marked with sensitive skin xan a skin with a reduced irritation threshold for irritants, such as hyperreactive and intolerant, but also atopic skin. A phenomenon called "stinging" (to sting = hurt, burn, hurt) can be observed in people with sensitive, sensitive or vulnerable skin. Typical disturbing phenomena associated with the terms "stinging" or "sensitive skin" are skin reddening, tingling, tingling, tightening and burning of the skin and itching. They can be caused by stimulating environmental conditions such as B. massage, surfactants, exposure to other chemical substances such. B. lactic acid, weather influences such as heat, cold, drought, but also damp heat, thermal radiation and UV radiation, z. B. the sun, or psychological stress.
„Empfindliche“ Kopfhaut ist ebenfalls gekennzeichnet durch Hautrötung, Kribbeln, Prickeln, Brennen und Juckreiz. Auslöser sind beispielsweise Seife, Shampoos oder andere Haarpflegemittel, Tenside, hartes Wasser mit hohen Kalkkonzentrationen und/oder mechanische Beanspruchung. Erytheme und Hyperseborrhoe (übermäßige Talgproduktion) der Kopfhaut sowie Schuppen sind häufig mit den beschriebenen Phänomenen assoziiert. “Sensitive” scalps are also characterized by skin redness, tingling, tingling, burning and itching. Triggers are, for example, soap, shampoo or other hair care products, surfactants, hard water with a high concentration of lime and/or mechanical stress. Erythema and hyperseborrhoea (excessive production of sebum) of the scalp and dandruff are often associated with the phenomena described.
Bei ca. 10-20% der Bevölkerung industrieller Länder, mit steigender Tendenz, ist die Atopie zu beobachten, eine familiär auftretende Überempfindlichkeit der Haut und der Schleimhäute gegen Umweltstoffe, mit gesteigerter Bereitschaft, gegen Substanzen aus der natürlichen Umwelt Überempfindlichkeitsreaktionen vom Soforttyp (Allergien) zu entwickeln. Atopie ist vermutlich genetisch bedingt. Atopie kann sich als atopische Dermatitis äußern. Dabei ist die Hautbarriere geschädigt, die Haut ist oft entzündet und juckt. Atopy, a familial hypersensitivity of the skin and mucous membranes to environmental substances, with an increased willingness to react to substances from the natural environment. to develop. Atopy is thought to be genetic. Atopy can manifest itself as atopic dermatitis. The skin barrier is damaged, the skin is often inflamed and itchy.
Die erythematöse Wirkung des ultravioletten Teils der Sonnenstrahlung oder künstlicher Strahlung auf die Haut ist allgemein bekannt. Während Strahlen mit einer Wellenlänge, die kleiner als 290 nm ist (der sogenannte UVC-Bereich), von der Ozonschicht in der Erdatmosphäre absorbiert werden, verursachen Strahlen im Bereich zwischen 290 nm und 320 nm, dem sogenannten UVB-Bereich, ein Erythem, einen einfachen Sonnenbrand oder sogar mehr oder weniger starke Verbrennungen. Erythematöse Hauterscheinungen treten auch als Begleiterscheinungen bei gewissen Hauterkrankungen oder -Unregelmässigkeiten auf, beispielsweise Akne, bakteriell induzierte Entzündungen der Haut, Kutanreaktionen, Dermographismus, das Wundsein der Haut im allgemeinen, Hautmaulwurf, Wundrose, Gürtelrose, Erfrierungen oder Verbrennungen. Eine besondere Form der Hautrötung stellt dabei die Rosacea dar. Antiinflammatorisch wirksame Zubereitungen können daher auch
vorteilhaft eingesetzt werden allgemein krankheitsbedingte Hautrötungen und im speziellen die Rosacea abklingen zu lassen, über einen längeren Zeitraum zu unterdrücken und das wieder Auftreten weitgehend zu verhindern. The erythematous effect of the ultraviolet part of solar radiation or artificial radiation on the skin is well known. While rays with a wavelength shorter than 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns. Erythematous skin manifestations also occur as side effects of certain skin diseases or irregularities, for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns. Rosacea is a special form of reddening of the skin. Anti-inflammatory preparations can therefore also are used to advantage in general, disease-related reddening of the skin and in particular rosacea to subside, to suppress them over a longer period of time and to largely prevent their recurrence.
Hautentzündungen, die mit Rötung und Juckreiz einhergehen, werden ebenfalls durch Insektenstiche hervorgerufen. Antinflammatorisch wirkende Mittel können daher auch dazu beitragen die Folgen eines Insektenstiches, wie z.B. Rötung, Quaddelbildung, Juckreiz und schmerzhafte Schwellungen der Haut, abklingen zu lassen, über einen längeren Zeitraum zu unterdrücken und das wieder Auftreten zu verhindern. Skin inflammation, which is accompanied by redness and itching, is also caused by insect bites. Anti-inflammatory agents can therefore also help to reduce the consequences of an insect bite, such as reddening, wheal formation, itching and painful swelling of the skin, suppress them over a longer period of time and prevent them from reoccurring.
Erytheme treten auch verstärkt im Windelbereich von Kleinkindern, umso mehr von Säuglingen auf (Windel Dematitis). Auch Inkontinenz, ein besonders im höheren Alter verstärkt auftretendes Leiden, ist häufig mit Erythemen und Hautrötung als Folge dauernder Exposition mit Feuchtigkeit und Reizstoffen verbunden (Inkontinenz Dermatitis). Erythemas also occur more frequently in the diaper area of small children, all the more so in infants (diaper dematitis). Incontinence, a condition that occurs more frequently in older people, is often associated with erythema and reddening of the skin as a result of constant exposure to moisture and irritants (incontinence dermatitis).
Zwar werden in den angesprochenen technischen Bereichen bereits eine Vielzahl Wirkstoffe mit hautirritationsverringernder Wirkung eingesetzt, doch wird weiterhin nach Alternativen gesucht. Although a large number of active ingredients with a skin irritation-reducing effect are already being used in the technical areas mentioned, alternatives are still being sought.
In der kosmetischen und pharmazeutischen Industrie besteht daher ein beständiger Bedarf an Mitteln mit hautirritationsverringernder Wirkung. Bei der Suche nach entsprechenden antiinflammatorisch wirksamen Mitteln ist dabei zu beachten, dass die in kosmetischen und/oder pharmazeutischen Produkten verwendeten Substanzen im Weiteren - toxikologisch unbedenklich, - gut hautverträglich, - stabil (insbesondere in üblichen kosmetischen und/oder pharmazeutischen Formulierungen), - vorzugsweise schwach riechend oder (weitgehend) geruchlos, - vorzugsweise farblos und nicht verfärbend, und - preiswert herstellbar (d.h. unter Einsatz von Standardverfahren und/oder ausgehend von Standardpräkursoren) sein müssen. In the cosmetic and pharmaceutical industry there is therefore a constant need for agents with a skin irritation-reducing effect. When searching for appropriate anti-inflammatory agents, it should be noted that the substances used in cosmetic and/or pharmaceutical products are - toxicologically harmless, - well tolerated by the skin, - stable (in particular in conventional cosmetic and/or pharmaceutical formulations), - preferably faintly odorous or (largely) odorless, - preferably colorless and non-discolouring, and - be inexpensive to produce (ie using standard processes and/or starting from standard precursors).
Die Suche nach geeigneten (Wirk-)substanzen, die eine oder mehrere der genannten Eigenschaften in ausreichendem Maße besitzen, ist dem Fachmann dadurch erschwert,
dass keine klare Abhängigkeit zwischen der chemischen Struktur einer Substanz einerseits und ihrer antiinflammatorischen Aktivität sowie ihrer Stabilität andererseits besteht. Des Weiteren gibt es keinen vorhersehbaren Zusammenhang zwischen der antiinflammatorischen Wirkung, der toxikologischen Unbedenklichkeit, der Hautverträglichkeit und/oder der Stabilität. The search for suitable (active) substances that have one or more of the properties mentioned to a sufficient extent is made more difficult for the person skilled in the art because that there is no clear relationship between the chemical structure of a substance on the one hand and its anti-inflammatory activity and stability on the other. Furthermore, there is no foreseeable connection between the anti-inflammatory effect, the toxicological safety, the skin compatibility and/or the stability.
Es war daher die Aufgabe der vorliegenden Erfindung, einen antiinflammatorischen Wirkstoff anzugeben, der vorzugsweise eine oder mehrere der vorab genannten Nebenbedingungen und besonders bevorzugt alle der vorab genannten Bedingungen erfüllt. It was therefore the object of the present invention to specify an anti-inflammatory active ingredient which preferably fulfills one or more of the aforementioned secondary conditions and particularly preferably all of the aforementioned conditions.
Die vorliegende Erfindung betrifft die Verwendung von topischen Zubereitungen zur Entfernung von Sebum von der Haut, insbesondere zur Beseitigung und Klärung von Comedonen, zur Vermeidung von Comedonenbildung, zur Prophylaxe und Behandlung leichter Formen der Akne sowie zur Prophylaxe und Bekämpfung der Seborrhöe. The present invention relates to the use of topical preparations for removing sebum from the skin, in particular for removing and clearing comedones, for preventing the formation of comedones, for the prophylaxis and treatment of mild forms of acne and for the prophylaxis and control of seborrhea.
Talgdrüsenüberproduktion und die möglichen sich daraus entwickelnden Hautstörungen wie Talgretention, Ausbildung von Comedonen im Gebiet der Talgdrüsen, also im Gesicht (vor allem Stirn, Nase und Kinn) und auf dem oberen Rücken und in der Folge die verschiedenen Formen der Akne, sind ein häufig anzutreffendes Hautproblem, das bisher nicht in zufriedenstellendem Masse gelöst worden ist. Overproduction of the sebaceous glands and the possible resulting skin disorders such as sebum retention, formation of comedones in the area of the sebum glands, i.e. on the face (especially forehead, nose and chin) and on the upper back and as a result the various forms of acne are a common occurrence Skin problem that has not yet been solved to a satisfactory extent.
Talg ist das Sekret der Talgdrüse. Talgdrüsen sind Ausbuchtungen des Follikelepithels und damit Bestandteile des Follikels, mit dem sie eine funktionelle Einheit bilden. Sie sind holokrine Drüsen, das bedeutet, die ganze Drüsenzelle wird zum größten Teil in das Sekret Talg umgewandelt. Die Zellen der Talgdrüse, die von unten her ständig erneuert werden, verfetten und zerfallen, und der so gebildete Hauttalg wird durch die Follikelmündungen auf die Hautoberflache entleert. Sebum is the secretion of the sebaceous gland. Sebaceous glands are bulges in the follicular epithelium and are therefore part of the follicle, with which they form a functional unit. They are holocrine glands, which means that most of the gland cell is converted into the secretion sebum. The cells of the sebaceous gland, which are constantly renewed from below, become fatty and disintegrate, and the skin sebum thus formed is emptied through the follicle openings onto the skin's surface.
Der Hauttalg besteht nach G. Leonardy (J.Ft. Jellinek Kosmetologie, Zweck und Aufbau kosmetischer Präparate, Dr. Alfred Hüthig- Verlag, Heidelberg - Mainz - Basel, dritter völlig überarbeiteter und wesentlich erweiterte Auflage 1976, Seiten 26 bis 29) aus Mono-, Di- und Triglyceriden (C10-C18), Wachsen (C16-C26), Wachsestern (C28-C38), normalen gesättigten Fettsäuren (C10-C18), verzweigtkettigen gesättigten Fettsäuren (C11-C18), mehrfach verzweigtkettigen gesättigten Fettsäuren (C13-C18), einfach ungesättigten Fettsäuren (C11-
C18), mehrfach ungesättigten Fettsäuren (C13, C15-C17), Sterolen (Cholesterin, 7- Dehydrocholesterin, 7-Hydroxycholesterin), verzweigten und unverzweigten Kohlenwasserstoffen (C30-C40), Squalen und Phospholipiden. According to G. Leonardy (J.Ft. Jellinek Kosmetologie, purpose and structure of cosmetic preparations, Dr. Alfred Hüthig-Verlag, Heidelberg - Mainz - Basel, third completely revised and significantly expanded edition 1976, pages 26 to 29), the sebum consists of mono -, di- and triglycerides (C 10 -C 18 ), waxes (C 16 -C 26 ), wax esters (C 28 -C 38 ), normal saturated fatty acids (C 10 -C 18 ), branched chain saturated fatty acids (C 11 - C 18 ), polybranched saturated fatty acids (C 13 -C 18 ), monounsaturated fatty acids (C 11 - C 18 ), polyunsaturated fatty acids (C 13 , C 15 -C 17 ), sterols (cholesterol, 7-dehydrocholesterol, 7-hydroxycholesterol), branched and unbranched hydrocarbons (C 30 -C 40 ), squalene and phospholipids.
Zusammen mit dem wässrigen Sekret der ekkrinen Schweißdrüsen bilden die Lipide der Talgdrüse den sogenannten Hydro-Lipid-Film der Haut. Dieser Oberflächenfilm ist eine Emulsion, die eine Wasser-in-ÖI oder eine Öl-in-Wasser-Emulsion sein kann. Sie hat die Funktion, die Hautoberfläche geschmeidig zu halten und den Wassergehalt der tieferliegenden Hautschichten zu regeln. Bei guter Hydratation des Sebums beträgt der Wassergehalt mindestens 10 bis 20 Gew.-% und das Sebum ist hydrophil. Ist das hydrophil- lipophile Gleichgewicht des Oberflächenfilmes nicht mehr gegeben und der Wassergehalt sinkt, so verändert sich das Sebum und wird hydrophob. Der Talgabfluss aus Talgdrüse und Follikel wird behindert. Es kommt zu einer Stauung des Hauttalgs in den Follikelmündungen, die dann in der Folge zu Comedonen und Entzündungen der Follikel führen kann. Together with the watery secretion of the eccrine sweat glands, the lipids of the sebaceous glands form the so-called hydro-lipid film of the skin. This surface film is an emulsion, which can be a water-in-oil or an oil-in-water emulsion. It has the function of keeping the skin's surface supple and regulating the water content of the deeper skin layers. When the sebum is well hydrated, the water content is at least 10 to 20% by weight and the sebum is hydrophilic. If the hydrophilic-lipophilic balance of the surface film is no longer given and the water content falls, the sebum changes and becomes hydrophobic. The flow of sebum from the sebaceous gland and follicle is impeded. The sebum accumulates in the follicle openings, which can then lead to comedones and inflammation of the follicles.
Die Veränderung des Hauttalgs und das Einleiten der Comedonenbildung kann verschiedene Ursachen haben. Zum Beispiel: äußere Einflüsse, wie falsche Reinigungsgewohnheiten und falsche Pflege, comedogene Substanzen in Kosmetika, Witterungseinflüsse, alkalische Seifen, scharfe Detergentien. Eine vermehrte Talgdrüsensekretion und die Ausbildung von Comedonen kann sich auch durch genetische Faktoren und hormonelle Einflüsse entwickeln. Auch hier können Comedonen, Entzündungen, Prä-Akne und Akne mit ihren Nachwirkungen die Folge sein. The change in the skin sebum and the initiation of the formation of comedones can have various causes. For example: external influences such as incorrect cleaning habits and incorrect care, comedogenic substances in cosmetics, weather influences, alkaline soaps, harsh detergents. Increased sebum secretion and the formation of comedones can also develop as a result of genetic factors and hormonal influences. Here, too, comedones, inflammation, pre-acne and acne with their after-effects can be the result.
Die Häufigkeit der Hautschäden durch eine gestörte Talgdrüsenfunktion und Krankheiten der Talgdrüsen steigen immer mehr, und die Rückführung/Vermeidung der Comedo-nenbildung ist somit ein vordringliches Anliegen. Doch bisherige Versuche, die Comedonenbildung als ein ursächliches Problem zu lösen, haben zu wenig befrie-digenden Ergebnissen geführt. The frequency of skin damage caused by a disturbed function of the sebaceous glands and diseases of the sebaceous glands is increasing, and the reduction/prevention of the formation of comedones is therefore a priority. However, previous attempts to solve comedone formation as a causal problem have led to unsatisfactory results.
Neben dem manuellen Entfernen der Comedonen durch Ausdrücken sind zahlreiche Reinigungsmethoden bekannt, mit denen versucht wird, Comedonen zu entfernen und die Comedonenbildung nachhaltig zu verhindern. Hierzu gehören spezielle Seifen, hautabschälende Kompositionen und dergleichen. Erweichende und adstringierende Mittel finden ebenso Anwendung. Darüberhinaus wird versucht, durch Zusatz von austrocknenden, keratolytischen, antiseborrhoischen und antibakteriellen Wirkstoffen in kosmetischen und pharmazeutischen Zubereitungen die Neigung zur Akne zu reduzieren, ohne dass sich
Irritationen der Haut oder ein Austrocknen der Haut einstellen. In addition to the manual removal of the comedones by squeezing, numerous cleaning methods are known with which attempts are made to remove comedones and to prevent the formation of comedones in the long term. These include special soaps, skin peeling compositions and the like. Emollients and astringents also find utility. In addition, attempts are being made to reduce the tendency to acne by adding drying, keratolytic, antiseborrheic and antibacterial active ingredients to cosmetic and pharmaceutical preparations, without Irritation of the skin or drying out of the skin.
Die Hautreinigung entfettet allerdings die Haut und entzieht ihr Feuchtigkeit. Zusätzlich haben Seifen den Nachteil, dass die sich bei Verwendung der Seifen in hartem Wasser bildenden wasserunlöslichen Calcium- und Magnesiumsalze der höheren Fettsäuren auf der Haut schleimige Niederschläge bilden. Diese Niederschläge verbleiben bei schlechter Abspülbarkeit länger auf der Haut, verstopfen die Follikelmündungen und können zu einer Ausbildung von Comedonen führen. Daher werden zur Hautreinigung vorwiegend Syndets (d.h., Tenside ohne Seifencharakter) in Form von Waschcremes oder Waschlotionen eingesetzt. Diese Syndets bilden zwar keine Kalkseifen, aber die Behandlung mit stark oberflächenaktiv wirkenden Agentien hat auf die Haut eine stärker entfettende und austrocknende Wirkung als Seife. Je häufiger seifen- und tensidhaltige Produkte auf der Haut angewandt werden, desto deutlicher treten deren nachteilige Wirkungen, nämlich Entfettung und Austrocknung der Haut durch Zerstörung des Hydro-Lipid-Filmes in den Vordergrund. Fast immer führt die Reduzierung der Comedonen zur Absenkung des Wassergehaltes in den oberen Hautschichten und zu einer festen Konkrementbildung in den Talgdrüsen, die wiederum Entzündungen induzieren kann. Die Absenkung des Feuchtigkeitsgehaltes der Haut ist aber für eine pflegende Entfernung der Comedonen kontraproduktiv. However, skin cleansing degreases the skin and removes moisture from it. In addition, soaps have the disadvantage that the water-insoluble calcium and magnesium salts of the higher fatty acids that form when the soaps are used in hard water form slimy deposits on the skin. If it is difficult to rinse off, these deposits remain on the skin longer, clog the follicle openings and can lead to the formation of comedones. For this reason, syndets (i.e. non-soap tensides) in the form of cleansing creams or cleansing lotions are predominantly used for skin cleansing. Although these syndets do not form lime soaps, treatment with highly surface-active agents has a stronger degreasing and drying effect on the skin than soap. The more frequently products containing soap and surfactants are used on the skin, the more clearly their adverse effects, namely degreasing and drying out of the skin through destruction of the hydro-lipid film, come to the fore. The reduction in comedones almost always leads to a reduction in the water content in the upper layers of the skin and to solid calculus formation in the sebaceous glands, which in turn can induce inflammation. However, lowering the moisture content of the skin is counterproductive for a caring removal of the comedones.
Seborrhöe ist eine gesteigerte Funktion der Talgdrüsen durch Veranlagung. Sowohl Kopfhaut als auch Gesichtshaut erscheinen fettig. Die Zusammensetzung des seborrhoeischen Sebums ist gegenüber dem normalen Sebum verändert, man unterscheidet 3 Entwicklungsstufen der Seborrhoe: Seborrhea is a predisposition to increased function of the sebaceous glands. Both scalp and facial skin appear greasy. The composition of seborrhoeic sebum is different from that of normal sebum. There are 3 stages of seborrhoea development:
1. einfache Seborrhöe Leichte Fälle, fettig nach 8 Tagen. 1. Simple Seborrhea Mild cases, greasy after 8 days.
2. ölige Seborrhöe Bereits nach 2-3 Tagen fettig. 2. Oily Seborrhea Already greasy after 2-3 days.
3. irreversible Form nicht mehr umkehrbar. Die Seborrhöe, bei der das Haar bereits nach einem Tag wie in Fett gebadet aussieht. 3. irreversible form no longer reversible. Seborrhea, in which the hair looks like it is bathed in grease after just one day.
Die übermäßige Absonderung der Talgdrüsen kann unter anderem durch androgenetische Störungen ausgelöst werden und hat einen ästhetischen Nachteil auf das Gesamtbild der Haare. Diese Störung kann auch die Ursache für auftretenden Haarausfall sein. Vorläufer ist jeweils der seborrhoeische Zustand der Kopfhaut. Vegetative Störungen sowie unsachgemäße Pflege können das Hautbild und auch den Haarzustand noch verschlechtern. Auch bei Seborrhöe kann das Haar selbst durch Störungen im Keratinaufbau trocken sein.
Trockenes, angegriffenes Haar wird häufig hervorgerufen durch äußere Beanspruchung wie z. B. Sonne oder chemischen Behandlungen. Zu heißes Föhnen oder nicht richtige Pflege von angegriffenem Haar können zu Schädigungen führen. The excessive secretion of the sebaceous glands can be triggered, among other things, by androgenetic disorders and has an aesthetic disadvantage on the overall appearance of the hair. This disorder can also be the cause of hair loss that occurs. The precursor to each is the seborrhoeic condition of the scalp. Vegetative disorders and improper care can worsen the complexion and hair condition. Even with seborrhea, the hair itself can be dry due to disturbances in the keratin structure. Dry, damaged hair is often caused by external stress such. B. sun or chemical treatments. Blow-drying that is too hot or not properly caring for damaged hair can lead to damage.
Die Ursachen für fettiges Haar liegen im Körper des Menschen und sind hormonell bedingt. Jedes Haar besitzt eine eigene Talgdrüse, die Fett (Sebum, Hauttalg) produziert. Die Sebum- Produktion wird hormonell gesteuert, und es kann je nach Hormonemp-findlichkeit der Talgdrüse zu einer Über- oder Unterproduktion kommen. Der Talg selber hat die Funktion die Kopfhaut geschmeidig zu halten. Er gelangt aus der Talgdrüse auf die Kopfhaut und erst später den Haaransatz. Dort wird er normalerweise vom Haarschaft aufgenommen und bleibt unsichtbar. Bei einer Talgüberproduktion ist der Haarschaft nicht mehr in der Lage diesen aufzunehmen. Er wird als Fettfilm am Haar sichtbar. Die Folge ist strähniges, fettig glänzendes Haar. The causes of greasy hair lie in the human body and are hormonal. Every hair has its own sebaceous gland, which produces fat (sebum, sebum). Sebum production is hormonally controlled, and depending on the hormone sensitivity of the sebaceous gland, there can be over- or underproduction. The sebum itself has the function of keeping the scalp supple. It gets from the sebaceous gland to the scalp and only later to the hairline. There it is normally absorbed by the hair shaft and remains invisible. When sebum is overproduced, the hair shaft is no longer able to absorb it. It becomes visible as a greasy film on the hair. The result is stringy, greasy, shiny hair.
Dadurch dass die Talgdrüsenproduktion vom Hormonhaushalt abhängig ist, lässt sich das Problem fettigen Haares nicht grundsätzlich lösen, denn die Talgdrüsen produzieren stetig Fett. Konsequente Pflege und hochwertige Pflegeserien sind immer noch die beste Methode zur Bekämpfung fettigen Haares. Because the production of the sebum depends on the hormonal balance, the problem of greasy hair cannot be solved in principle, because the sebum is constantly producing fat. Consistent care and high-quality care series are still the best way to combat oily hair.
Fettiges Haar hat sehr lästige Auswirkungen. Die Haare werden schon kurze Zeit nach dem Waschen wieder strähnig und die Frisur hält nicht. Greasy hair has very annoying effects. The hair becomes stringy again a short time after washing and the hairstyle does not last.
Entgegen landläufiger Meinung ist es nur ein Gerücht, dass durch zu häufiges Waschen das Haar noch schneller fettig wird. Milde Shampoos gegen fettiges Haar sorgen dafür, dass übermäßiges Fett entfernt wird. Haar und Kopfhaut werden mit ausreichend Feuchtigkeit versorgt und gleichen die Überproduktion der Talgdrüsen aus. Contrary to popular belief, it's just a rumor that washing your hair too often will make your hair greasy even faster. Mild shampoos for oily hair ensure that excess oil is removed. Hair and scalp are supplied with sufficient moisture and balance the overproduction of the sebaceous glands.
Fettiges Haar und Schuppenbildung gehören zu den häufigsten Haarproblemen. Diese Ano- malien sind auf eine Störung der Talgdrüsentätigkeit zurückzuführen. Bei einer Überfunktion der Talgdrüsen sprechen wir von einer Seborrhoe. Dabei sind zwei Formen zu unterscheiden: die ölige Form (Seborrhöe oleosa) und die trockene Form (Seborrhöe sicca ). Greasy hair and dandruff are among the most common hair problems. These anomalies are due to a disturbance in the activity of the sebaceous glands. If the sebaceous glands are overactive, we speak of seborrhea. There are two forms to be distinguished: the oily form (seborrhea oleosa) and the dry form (seborrhea sicca).
Die Seborrhoea oleosa: Oleosa seborrhoea:
Hier liegt eine Überfunktion der Talgdrüsen vor, bei der die Talgdrüsen zu viel und zu öligen Talg erzeugen. Die Haut zeigt deshalb einen fettigen Glanz, und die Haare sind schon 2 bis 3
Tage nach der Wäsche wieder bis in die Spitzen fettig und strähnig. Here there is an overfunction of the sebaceous glands, in which the sebaceous glands produce too much and too oily sebum. The skin therefore has a greasy shine and the hair is already 2 to 3 years old Days after washing again greasy and stringy to the tips.
Die Seborrhoea sicca: The seborrhoea sicca:
Sie ist ebenfalls auf eine Überfunktion der Talgdrüsen zurückzuführen, aber der Hauttalg ist trockener, er hat eine festere Konsistenz. Mit den Schüppchen der Oberhaut bildet er große, leicht zerreibbare Talgschuppen. Die Kopfhaut zeigt einen wachsartigen Glanz, das Haar fettet nur am Ansatz nach, die Längen und besonders die Spitzen sind trocken und sogar spröde. It is also due to overactive sebaceous glands, but the sebum is drier and has a firmer consistency. With the scales of the epidermis, it forms large, easily crushable sebum scales. The scalp has a waxy shine, the hair only becomes greasy at the roots, the lengths and especially the ends are dry and even brittle.
Zur Behandlung der Seborrhöe gehört zunächst mal die regelmäßige und gründliche Kopfwäsche mit Spezialshampoos, die so oft durchgeführt werden kann, wie es nötig erscheint. Die Wäsche sollte mit einer Massage im Bindegewebe verbunden sein, weil dadurch dir Talgdrüsen stärker entleert werden, was die Nachfettung verzögert. The treatment of seborrhea includes, first of all, regular and thorough washing of the head with special shampoos, which can be carried out as often as seems necessary. The wash should be combined with a massage in the connective tissue, because this empties the sebaceous glands more, which delays the subsequent greasing.
Der vorliegenden Erfindung liegt die Aufgabe zugrunde, eine Zubereitung zur Verfügung zu stellen, die die Nachteile der bekannten und bisher verwendeten Mittel nicht aufweist, die gleichzeitig talglösend, fettregulierend und pflegend wirkt, die bereits vorhandenen Comedonen ohne Irritationen entfernt, die Entfettung und Austrocknung der Haut wirksam verhindert, die Comedonenbildung und die Entstehung von Akne Kosmetika verhindert, sowie schon bestehende Akne bessert und die gleichwertig die Haut pflegt. The object of the present invention is to provide a preparation that does not have the disadvantages of the known and previously used agents, which simultaneously has a sebum-dissolving, fat-regulating and caring effect, removes existing comedones without irritation, and degreases and dehydrates the skin effectively prevents the formation of comedones and the development of acne cosmetics, as well as improves existing acne and cares for the skin in the same way.
Es hat sich überraschenderweise herausgestellt, dass die Aufgaben gelöst werden durch
Surprisingly, it turned out that the tasks can be solved by
Isobutyramide der allgemeinen Formel wobei n: bedeutet, dass 1 bis 5 gleiche und/oder unterschiedliche Substituenden R1 zugegen sein
können, wobei der einzelne oder die mehreren Substituenden R1 : unabhängig voneinander bedeuten können: OH, CH3, O- CH3, O-(CO)-CH3 (Acetyl), wobei Isobutyramides of the general formula where n: means that 1 to 5 identical and/or different substituents R 1 are present can, where the single or multiple substituents R 1 : independently of one another can mean: OH, CH 3 , O-CH 3 , O- (CO) -CH 3 (acetyl), wherein
R2 : H oder eine C1 - C4 - Alkylkette bedeuten kann, und wobei R 2 : H or a C 1 - C 4 - alkyl chain, and where
R3 : H oder CH3 bedeuten kann, wobei aber das Isobutyramid der Struktur ausgeschlossen ist. R 3 can be H or CH 3 but excludes the isobutyramide of the structure.
Die erfindungsgemäßen Isobutyramide sind hervorragende Wirkstoffe zur Prophylaxe vor und Behandlung von sensibler Haut, Juckreiz, sowie von entzündlichen Erscheinung in der menschlichen Haut. The isobutyramides according to the invention are excellent active ingredients for the prophylaxis and treatment of sensitive skin, itching and inflammatory phenomena in human skin.
Überraschenderweise wird außerdem bei Verwendung der Zubereitung die comedogene Wirkung der in der Zubereitung verwendeten Rohstoffe aufgehoben und damit die Bildung von Comedonen und entsprechend die Entstehung von Akne verhindert. Surprisingly, when the preparation is used, the comedogenic effect of the raw materials used in the preparation is also eliminated and the formation of comedones and, accordingly, the development of acne is thus prevented.
Es hat sich ferner herausgestellt, dass die erfindungsgemäß verwendeten Wirkstoffe die Bil- dung von seborrhoischen Erscheinungen, insbesondere fettiges Haar, aber auch Kopfschup- pen, verhindern sowie bereits vorhandene seborrhoische Erscheinungen, insbesondere fettiges Haar, aber auch Kopfschuppen, zu beseitigen. It has also been found that the active ingredients used according to the invention prevent the formation of seborrheic phenomena, particularly greasy hair but also dandruff, and eliminate existing seborrheic phenomena, particularly greasy hair but also dandruff.
Darüber hinaus gewährleistet die vorliegende Erfindung eine sehr gute Hautpflege, verbunden mit einer effizienten Entfernung überschüssigen Hauttalgs. In addition, the present invention ensures very good skin care, combined with efficient removal of excess skin sebum.
Erfindungsgemäß sind somit auch ein Verfahren zur Bekämpfung von unreiner Haut, Akne, oder seborrhioschen Erscheinungen, insbesondere fettigem Haar und/oder Kopfschuppen, dadurch gekennzeichnet, dass die erfindungsgemäß verwendeten Wirkstoffe in einem geeig- neten kosmetischen oder dermatologischen Träger, mit dem von gesteigerte Sebumproduktion betroffenen Bereich in Kontakt gebracht werden.
Der Stand der Technik lieferte nicht den geringsten Hinweis auf die erfindungsgemäße Verwendung als antiseborrhoisches Wirkprinzip. According to the invention, a method for combating impure skin, acne, or seborrheic phenomena, in particular greasy hair and/or dandruff, is characterized in that the active ingredients used according to the invention are in a suitable cosmetic or dermatological vehicle with which the increased sebum production is affected Area to be contacted. The prior art did not provide the slightest indication of the use according to the invention as an antiseborrheic principle of action.
Eine weitere bevorzugte Ausführungsform der vorliegenden Erfindung sind mithin gegen Kopfschuppen anzuwendende Formulierungen, beispielsweise Antischuppenshampoos. A further preferred embodiment of the present invention are therefore formulations to be used against dandruff, for example anti-dandruff shampoos.
Die EP 3 176 156 A1 beschreibt ähnliche Isobutyramide, allerdings sind die erfindungsgemä- ßen Substanzen nicht in dieser Schrift konkret offenbart. EP 3 176 156 A1 describes similar isobutyramides, but the substances according to the invention are not specifically disclosed in this document.
Ferner ist die in der EP 3 176 156 A1 offenbarte Wirkung die Verminderung der Hautpigmen- tierung. Diese Wirkung tritt aber bei den (hier) erfindungsgemäßen Isobutyramiden nicht auch, wäre auch erfindungsgemäß unerwünscht. Furthermore, the effect disclosed in EP 3 176 156 A1 is the reduction in skin pigmentation. However, this effect does not occur with the (here) isobutyramides according to the invention and would also be undesirable according to the invention.
Bevorzugt enthalten kosmetische oder dermatologische Zubereitungen gemäß der Erfindung 0,000001 bis 10 Gew.-%, besonders bevorzugt 0,0001 bis 3 Gew.-%, und ganz besonders bevorzugt 0,001 bis 1 Gew.-%, an Isobutyramiden, bezogen auf das Gesamtgewicht der Zu- bereitungen. Cosmetic or dermatological preparations according to the invention preferably contain 0.000001 to 10% by weight, particularly preferably 0.0001 to 3% by weight and very particularly preferably 0.001 to 1% by weight of isobutyramides, based on the total weight of the preparations.
Bei Anwendung der erfindungsgemäß verwendeten Wirkstoffe bzw. kosmetischer oder topi- scher dermatologischer Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwendeter Wirkstoffe ist in überraschender Weise eine wirksame Behandlung von, aber auch eine Prophylaxe bei defizitären, sensitiven oder hypoaktiven Hautzuständen oder defizitären, sensitiven oder hypoaktiven Zustände von Hautanhangsgebilde und/oder entzündlichen Erscheinungen und/oder Juckreiz möglich. When using the active ingredients used according to the invention or cosmetic or topical dermatological preparations with an effective content of active ingredients used according to the invention, surprisingly there is an effective treatment of, but also prophylaxis in, deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive conditions of skin appendages and/or inflammatory phenomena and/or itching possible.
Es ist erfindungsgemäß insbesondere äußerst vorteilhaft, ein oder mehrere erfin- dungsgemäße Isobutyramide bzw. kosmetische oder topische dermatologische Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäßen Isobutyramiden zur kosmetischen oder dermatologischen Behandlung oder Prophylaxe unerwünschter Hautzu- stände zu verwenden. It is particularly extremely advantageous according to the invention to use one or more isobutyramides according to the invention or cosmetic or topical dermatological preparations with an effective content of isobutyramides according to the invention for the cosmetic or dermatological treatment or prophylaxis of undesired skin conditions.
Vorteilhafte Isobutyramide im Sinne der vorliegenden Erfindung sind folgende Substanzen:
Verbindung 1 Advantageous isobutyramides for the purposes of the present invention are the following substances: connection 1
Verbindung 2connection 2
Verbindung 3
connection 3
Verbindung 4
connection 4
Verbindung 5
connection 5
Verbindung 6
Verbindung 7
connection 6 connection 7
Verbindung 8
connection 8
Verbindung 9
Verbindung 10
connection 9 connection 10
Verbindung 11
connection 11
Verbindung 12
N-(4-(2,4-Dihvdroxy-3-methylphenyl)thiazol-2-yl)-isobutyramid connection 12 N-(4-(2,4-Dihydroxy-3-methylphenyl)thiazol-2-yl)isobutyramide
Verbindung 13
connection 13
Die Prophylaxe bzw. die kosmetische oder dermatologische Behandlung mit dem erfin- dungsgemäß verwendeten Wirkstoff bzw. mit den kosmetischen oder topischen derma- tologischen Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwendetem Wirkstoff erfolgt in der üblichen Weise, und zwar dergestalt, dass der erfindungsgemäß verwendete Wirkstoff bzw. die kosmetischen oder topischen dermatologischen Zu- bereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwendetem Wirkstoff auf die betroffenen Hautstellen aufgetragen wird. The prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention takes place in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
Vorteilhaft kann der erfindungsgemäß verwendete Wirkstoff eingearbeitet werden in übliche kosmetische und dermatologische Zubereitungen, welche in verschiedenen Formen vorliegen können. So können sie z. B. eine Lösung, eine Emulsion vom Typ Wasser-in-ÖI (W/O) oder vom Typ Öl-in-Wasser (O/W), oder eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-ÖI-in-Wasser (W/O/W) oder Öl-in-Wasser-in-ÖI (O/W/O), eine Hydrodispersi- on oder Lipodispersion, eine Pickering-Emulsion, ein Gel, einen festen Stift oder auch ein Aerosol darstellen. The active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be present in various forms. So you can e.g. a solution, an emulsion of the water-in-oil (W/O) or oil-in-water (O/W) type, or a multiple emulsion, for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O), a hydrodispersion or lipodispersion, a Pickering emulsion, a gel, a solid stick or an aerosol.
Erfindungsgemäße Emulsionen im Sinne der vorliegenden Erfindung, z. B. in Form einer Creme, einer Lotion, einer kosmetischen Milch sind vorteilhaft und enthalten z. B. Fette, Öle, Wachse und/oder andere Fettkörper, sowie Wasser und einen oder mehrere Emulgatoren,
wie sie üblicherweise für einen solchen Typ der Formulierung verwendet werden. Emulsions according to the invention for the purposes of the present invention, e.g. B. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain z. B. fats, oils, waxes and/or other fatty substances, as well as water and one or more emulsifiers, as commonly used for such type of formulation.
Es ist auch möglich und vorteilhaft im Sinne der vorliegenden Erfindung, den erfindungs- gemäß verwendeten Wirkstoff in wässrige Systeme bzw. Tensidzubereitungen zur Reinigung der Haut und der Haare einzufügen. It is also possible and advantageous for the purposes of the present invention to add the active ingredient used according to the invention to aqueous systems or surfactant preparations for cleaning the skin and hair.
Es ist dem Fachmann natürlich bekannt, dass anspruchsvolle kosmetische Zusammen- setzungen zumeist nicht ohne die üblichen Hilfs- und Zusatzstoffe denkbar sind. Darunter zählen beispielsweise Konsistenzgeber, Füllstoffe, Parfum, Farbstoffe, Emulgatoren, zusätzliche Wirkstoffe wie Vitamine oder Proteine, Lichtschutzmittel, Stabilisatoren, Insek- tenrepellentien, Alkohol, Wasser, Salze, antimikrobiell, proteolytisch oder keratolytisch wirksame Substanzen usw. It is of course known to the person skilled in the art that demanding cosmetic compositions are mostly unthinkable without the usual auxiliaries and additives. These include, for example, consistency enhancers, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, sunscreens, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances, etc.
Mutatis mutandis gelten entsprechende Anforderungen an die Formulierung medizinischer Zubereitungen. Mutatis mutandis, corresponding requirements apply to the formulation of medicinal preparations.
Medizinische topische Zusammensetzungen im Sinne der vorliegenden Erfindung enthalten in der Regel ein oder mehrere Medikamente in wirksamer Konzentration. Der Einfachheit halber wird zur sauberen Unterscheidung zwischen kosmetischer und medizinischer Anwendung und entsprechenden Produkten auf die gesetzlichen Bestimmungen der Bundesrepublik Deutschland verwiesen (z. B. Kosmetikverordnung, Lebensmittel- und Arzneimittelgesetz). Medicinal topical compositions within the meaning of the present invention usually contain one or more medicaments in an effective concentration. For the sake of simplicity, reference is made to the legal provisions of the Federal Republic of Germany (e.g. Cosmetics Ordinance, Food and Drugs Act) for a clear distinction between cosmetic and medical use and corresponding products.
Es ist dabei ebenfalls von Vorteil, den erfindungsgemäß verwendeten Wirkstoff als Zu- satzstoff zu Zubereitungen zu geben, die bereits andere Wirkstoffe für andere Zwecke enthalten. It is also advantageous here to add the active substance used according to the invention as an additive to preparations which already contain other active substances for other purposes.
Entsprechend können kosmetische oder topische dermatologische Zusammensetzungen im Sinne der vorliegenden Erfindung, je nach ihrem Aufbau, beispielsweise verwendet werden als Hautschutzcreme, Reinigungsmilch, Sonnenschutzlotion, Nährcreme, Tages- oder Nachtcreme usw. Es ist gegebenenfalls möglich und vorteilhaft, die erfindungsgemäßen Zu- sammensetzungen als Grundlage für pharmazeutische Formulierungen zu verwenden. Correspondingly, cosmetic or topical dermatological compositions according to the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day or night cream, etc. It is optionally possible and advantageous to use the compositions according to the invention as a basis to use for pharmaceutical formulations.
Zur Anwendung werden die kosmetischen und dermatologischen Zubereitungen erfindungs- gemäß in der für Kosmetika üblichen Weise auf die Haut und/oder die Haare in ausreichen-
der Menge aufgebracht. For use, the cosmetic and dermatological preparations according to the invention are applied to the skin and/or the hair in sufficient amounts in the manner customary for cosmetics. upset by the crowd.
Besonders bevorzugt sind solche kosmetischen und dermatologischen Zubereitungen, die in der Form eines Sonnenschutzmittels vorliegen. Vorteilhaft können diese zusätzlich minde- stens einen weiteren UVA-Filter und/oder mindestens einen weiteren UVB-Filter und/oder mindestens ein anorganisches Pigment, bevorzugt ein anorganisches Mikropigment, enthal- ten. Those cosmetic and dermatological preparations which are in the form of a sunscreen are particularly preferred. Advantageously, these can additionally contain at least one further UVA filter and/or at least one further UVB filter and/or at least one inorganic pigment, preferably an inorganic micropigment.
Die kosmetischen und dermatologischen Zubereitungen können erfindungsgemäß kosmeti- sche Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z.B. Konservierungsmittel, Bakterizide, Parfüme, Substanzen zum Verhindern des Schäumens, Farbstoffe, Pigmente, die eine färbende Wirkung haben, Verdickungsmittel, an- feuchtende und/oder feuchthaltende Substanzen, Fette, Öle, Wachse oder andere übliche Bestandteile einer kosmetischen oder dermatologischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate. According to the invention, the cosmetic and dermatological preparations can contain cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Ein zusätzlicher Gehalt an üblichen Antioxidantien ist im Allgemeinen bevorzugt. Erfindungs- gemäß können als günstige Antioxidantien alle für kosmetische und/oder dermatologische Anwendungen geeigneten oder gebräuchlichen Antioxidantien verwendet werden. An additional content of customary antioxidants is generally preferred. According to the invention, all antioxidants that are suitable or customary for cosmetic and/or dermatological applications can be used as favorable antioxidants.
Die Menge der vorgenannten Antioxidantien (eine oder mehrere Verbindungen) in den Zube- reitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05 -The amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 -
20 Gew.-%, insbesondere 1 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung. 20% by weight, in particular 1-10% by weight, based on the total weight of the preparation.
Sofern die kosmetische oder dermatologische Zubereitung im Sinne der vorliegenden Erfin- dung eine Lösung oder Emulsion oder Dispersion darstellt, können als Lösungsmittel verwendet werden: If the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
Wasser oder wässrige Lösungen water or aqueous solutions
Öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizinusöl;Oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;
Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propylenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren; Fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols with a low carbon number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids;
Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Etha- nol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmonoethyl- oder
-monobutylether, Propylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethylenglykolmonomethyl- oder -monoethylether und analoge Produkte. Alcohols, diols or polyols with a low carbon number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein. In particular, mixtures of the aforementioned solvents are used. In the case of alcoholic solvents, water can also be an additional component.
Sofern die kosmetische oder dermatologische Zubereitung im Sinne der vorliegenden Erfin- dung eine Lösung oder Emulsion oder Dispersion darstellt, können als Lösungsmittel verwendet werden: - Wasser oder wäßrige Lösungen - Öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizinusöl; - Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propylenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren; - Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Etha- nol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmonoethyl- oder -monobutylether, Propylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethylenglykolmonomethyl- oder -monoethylether und analoge Produkte. If the cosmetic or dermatological preparation according to the present invention is a solution or emulsion or dispersion, the following solvents can be used: water or aqueous solutions oils such as triglycerides of capric or caprylic acid, but preferably castor oil; - fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols with a low carbon number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids; - Alcohols, diols or polyols with a low carbon number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogs Products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein. In particular, mixtures of the aforementioned solvents are used. In the case of alcoholic solvents, water can also be an additional component.
Als Treibmittel für aus Aerosolbehältern versprühbare kosmetische und/oder dermato- logische Zubereitungen im Sinne der vorliegenden Erfindung sind die üblichen bekannten leichtflüchtigen, verflüssigten Treibmittel, beispielsweise Kohlenwasserstoffe (Propan, Butan, Isobutan) geeignet, die allein oder in Mischung miteinander eingesetzt werden können. Auch Druckluft ist vorteilhaft zu verwenden. For the purposes of the present invention, suitable propellants for cosmetic and/or dermatological preparations that can be sprayed from aerosol containers are the customary, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Compressed air is also advantageous to use.
Natürlich weiß der Fachmann, dass es an sich nichttoxische Treibgase gibt, die grundsätzlich für die Verwirklichung der vorliegenden Erfindung in Form von Aerosolpräparaten geeignet wären, auf die aber dennoch wegen bedenklicher Wirkung auf die Umwelt oder sonstiger Be- gleitumstände verzichtet werden sollte, insbesondere Fluorkohlenwasserstoffe und Fluor- chlorkohlenwasserstoffe (FCKW).
Kosmetische Zubereitungen im Sinne der vorliegenden Erfindung können auch als Gele vorliegen, die neben einem wirksamen Gehalt am erfindungsgemäßen Wirkstoff und dafür üblicherweise verwendeten Lösungsmitteln, bevorzugt Wasser, noch organische Ver- dickungsmittel, z.B. Gummiarabikum, Xanthangummi, Natriumalginat, Cellulose-Derivate, vorzugsweise Methylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Hydroxypro- pylcellulose, Hydroxypropylmethylcellulose oder anorganische Verdickungsmittel, z. B. Alu- miniumsilikate wie beispielsweise Bentonite, oder ein Gemisch aus Polyethylenglykol und Polyethylenglykolstearat oder -distearat, enthalten. Das Verdickungsmittel ist in dem Gel z.B. in einer Menge zwischen 0,1 und 30 Gew.-%, bevorzugt zwischen 0,5 und 15 Gew.-%, enthalten. Of course, the person skilled in the art knows that there are non-toxic propellants that would be suitable in principle for the realization of the present invention in the form of aerosol preparations, but which should nevertheless be avoided because of the questionable effect on the environment or other accompanying circumstances, in particular fluorocarbons and chlorofluorocarbons (CFCs). Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents customarily used for this purpose, preferably water, also organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, Hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose or inorganic thickeners, e.g. B. aluminum miniumsilicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate. The thickening agent is contained in the gel, for example, in an amount of between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
Es ist erfindungsgemäß vorteilhaft, außer den erfindungsgemäßen Kombinationen weitere öllösliche UVA-Filter und/oder UVB-Filter in der Lipidphase und/oder weitere wasserlösliche UVA-Filter und/oder UVB-Filter in der wäßrigen Phase einzusetzen. It is advantageous according to the invention to use other oil-soluble UVA filters and/or UVB filters in the lipid phase and/or other water-soluble UVA filters and/or UVB filters in the aqueous phase in addition to the combinations according to the invention.
Vorteilhaft können die Lichtschutzformulierungen erfindungsgemäß weitere Substanzen enthalten, die UV-Strahlung im UVB-Bereich absorbieren, wobei die Gesamtmenge der Filtersubstanzen z.B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 10 Gew.-%, insbe- sondere 1 bis 6 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnenschutzmittel dienen. According to the invention, the light protection formulations can advantageously contain further substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
Wirkungsnachweis: Proof of effectiveness:
Die Wirkung der Derivate wurde mit einigen Testverfahren untersucht, deren Relevanz für kosmetische Fragestellungen sich in den letzten Jahren vielfach gezeigt hat und die bei Kolbe et al. (Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects. Kolbe L et al., Arch Dermatol Res. 2006 Jun;298(1):23-30) im Detail beschrieben sind. Prostaglandine (PG) sind Entzündungsmediatoren, die rasch aus der Arachidonsäure gebildet werden können und Rötungen und Schmerzempfinden verstärken können. In der Haut ist insbesondere die Reduktion der Freisetzung von PGE2 zur Vermeidung oder Minderung von Entzündungen angeraten.
Fig 1 demonstriert die Reduktion der LPS-stimulierten PGE2 Produktion in humanen dermalen Fibroblasten The effect of the derivatives was examined using a number of test methods, the relevance of which for cosmetic issues has been shown many times in recent years and which are used by Kolbe et al. (Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects. Kolbe L et al., Arch Dermatol Res. 2006 Jun;298(1):23-30) are described in detail. Prostaglandins (PG) are inflammatory mediators that can be rapidly formed from arachidonic acid and can increase redness and pain. In the skin, in particular, reducing the release of PGE 2 is advisable to avoid or reduce inflammation. 1 demonstrates the reduction in LPS-stimulated PGE 2 production in human dermal fibroblasts
Aus der Arachidonsäure können in der Haut durch einwandernde neutrophile Granulozyten auch Leukotriene gebildet werden, die ebenfalls entzündungsfördernd sind. Deshalb ist für eine effiziente Wirksamkeit auch eine Reduktion der Leukotriene, insbesondere von LTB4 angeraten. Leukotrienes, which also promote inflammation, can also be formed from arachidonic acid in the skin by migrating neutrophilic granulocytes. Therefore, a reduction in leukotrienes, especially LTB 4 , is recommended for efficient effectiveness.
Fig 2 demonstriert die Reduktion der Ca-lonophor-stimulierten LTB4 Figure 2 demonstrates the reduction of Ca ionophore-stimulated LTB 4
Granulozyten sind die ersten Immunzellen, die nach einem entzündlichen Stimulus in die Haut einwandern. Der „oxidative Burst“ der Granulozyten ist zwar sehr wichtig für die Infektionsabwehr, allerdings kann ein überschießender Burst im Gewebe große Kollateralschäden verursachen. Bei heftigen Entzündungen kann es deshalb angeraten sein mittels anti-entzündlicher Substanzen diese Reaktion zu dämpfen. Granulocytes are the first immune cells to migrate into the skin after an inflammatory stimulus. Although the "oxidative burst" of the granulocytes is very important for the defense against infection, an excessive burst in the tissue can cause major collateral damage. In the case of severe inflammation, it may therefore be advisable to dampen this reaction with anti-inflammatory substances.
Fig 3 demonstriert die Reduktion des „oxidativen Bursts“ von fMLP-stimulierten neutrophilen Granulozyten Fig. 3 demonstrates the reduction of the "oxidative burst" of fMLP-stimulated neutrophils
Den Abbildungen 1-3 ist zu entnehmen, dass die beanspruchten Isobutyramide in den genannten Tests eine überaus positive anti-entzündliche Wirkung zeigen.
It can be seen from Figures 1-3 that the claimed isobutyramides show an extremely positive anti-inflammatory effect in the tests mentioned.
Svnthesevorschriften exemplarisch ausgewählter Isobutyramide: Synthesis instructions for exemplarily selected isobutyramides:
Verbindung 1 : N-(4-(2-Hvdroxy-4-methoxyphenyl)thiazol-2-yl)-isobutyramid Compound 1 : N-(4-(2-Hydroxy-4-methoxyphenyl)thiazol-2-yl)-isobutyramide
Schritt 01
step 01
114 g (1.5 mol) Thioharnstoff wurden in Toluol (800 ml) vorgelegt und 80 g (0.75 mol) Isobutyrylchlorid zugetropft. Die Reaktionslösung wurde 3 Stunden unter Rückfluss gekocht, wobei 2 Phasen entstehen. Die obere Phase wurde abdekantiert und abgekühlt. Die ausgefallenen weißen Kristalle wurden abgesaugt und mit Toluol gewaschen und im Vakuum getrocknet. Ausbeute: 62 g. 1H NMR (DMSO-D6): 11.03 (bs, 1 H), 9.66 (bs, 1 H), 9.35 (bs, 1 H), 2.72 (m, 1 H), 1.03 (2, 6H) ppm; 114 g (1.5 mol) of thiourea were placed in toluene (800 ml) and 80 g (0.75 mol) of isobutyryl chloride were added dropwise. The reaction solution was refluxed for 3 hours, resulting in 2 phases. The upper phase was decanted and cooled. The white crystals which had separated out were filtered off with suction, washed with toluene and dried in vacuo. Yield: 62 g. 1 H NMR (DMSO-D 6 ): 11.03 (bs, 1H), 9.66 (bs, 1H), 9.35 (bs, 1H), 2.72 (m, 1H), 1.03 (2, 6H) ppm;
Schritt 02
step 02
Schritt 03
Verbindung 2: N-(4-(2,4-bis(methoxy)phenyl)thiazol-2-yl)-isobutyramid Schritt 01
Schritt 02
Schritt 03
Verbindungen 12 und 13 Schritt 01
Schritt 02
oder
step 03 Compound 2: N-(4-(2,4-bis(methoxy)phenyl)thiazol-2-yl)isobutyramide Step 01 step 02 step 03 Connections 12 and 13 step 01 step 02 or
Schritt 03
step 03
oder
Schritt 04
or step 04
Die nachfolgenden Beispiele sollen die vorliegende Erfindung verdeutlichen, ohne sie einzuschränken. Alle Mengenangaben, Anteile und Prozentanteile sind, soweit nicht anders angegeben, auf das Gewicht und die Gesamtmenge bzw. auf das Gesamtgewicht der Zubereitungen bezogen.
The following examples are intended to illustrate the present invention without restricting it. Unless otherwise stated, all amounts, proportions and percentages are based on the weight and the total amount or the total weight of the preparations.
Rezepturbeispielerecipe examples
O/W -Emulsionen
W/O Emulsionen
Wässrig-Ethanolische Lösung für beispielsweise Stift- /Applikator- / Pinsel-Anwendung
O/W emulsions W/O emulsions Aqueous-ethanolic solution for e.g. pen/applicator/brush application
Claims
Patentansprüche 1. Isobutyramide der allgemeinen Formel
wobei n : bedeutet, dass 1 bis 5 gleiche und/oder unterschiedliche Substituenden R1 zugegen sein können, wobei der einzelne oder die mehreren Substituenden R1 : unabhängig voneinander bedeuten können: OH, CH3, O-CH3, O-(CO)-CH3 (Acetyl), wobei R2 : H oder eine C1 - C4 - Alkylkette bedeuten kann, und wobei R3 : H oder CH3 bedeuten kann, wobei aber das Isobutyramid der Struktur
ausgeschlossen ist.
Claims 1. Isobutyramides of the general formula where n: means that 1 to 5 identical and/or different substituents R 1 can be present, where the single or multiple substituents R 1 : can mean independently of one another: OH, CH 3 , O-CH 3 , O-(CO )-CH 3 (acetyl), where R 2 can mean: H or a C 1 -C 4 - alkyl chain, and where R 3 can mean: H or CH 3 , but where the isobutyramide of the structure is excluded.
2. Isobutyramide nach Anspruch 1 , gewählt aus der Gruppe2. isobutyramides according to claim 1, selected from the group
Verbindung 1
connection 1
Verbindung 2
connection 2
Verbindung 3
Verbindung 4
connection 3 connection 4
Verbindung 5
connection 5
Verbindung 6
connection 6
Verbindung 7
connection 7
Verbindung 8
connection 8
Verbindung 9
connection 9
Verbindung 10
connection 10
Verbindung 11
connection 11
Verbindung 12
Verbindung 13
connection 12 connection 13
3. Kosmetische oder dermatologische Zubereitungen, enthaltend Isobutyramide nach Anspruch 1 oder 2, wobei der Gehalt an Isobutyramiden in den kosmetischen oder dermatologischen Zubereitungen aus dem Bereich von 0,000001 bis 10,0 Gew.-%, insbesondere von 0,0001 bis 3,0 Gew.-% und ganz besonders von 0,001 bis 1 Gew.-% gewählt wird, jeweils bezogen auf das Gesamtgewicht der Zusammensetzung. 3. Cosmetic or dermatological preparations containing isobutyramides according to Claim 1 or 2, the content of isobutyramides in the cosmetic or dermatological preparations being in the range from 0.000001 to 10.0% by weight, in particular from 0.0001 to 3 0% by weight and more particularly from 0.001 to 1% by weight, based on the total weight of the composition.
4. Verwendung von Isobutyramiden nach Anspruch 1 oder 2 oder von Zubereitungen nach Anspruch 3 zur Prophylaxe vor und Behandlung von sensibler Haut, Juckreiz, trockener Haut, sowie von entzündlichen Erscheinung in der menschlichen Haut. 4. Use of isobutyramides according to claim 1 or 2 or of preparations according to claim 3 for the prophylaxis and treatment of sensitive skin, itching, dry skin and inflammatory phenomena in human skin.
5. Verwendung von Isobutyramiden nach Anspruch 1 oder 2 oder von Zubereitungen nach Anspruch 3 zur Prophylaxe vor und Behandlung vonzur Verminderung der Produktion von Sebum bzw. die Verwendung von Cyclodextrinen zur Herstellung von Zubereitungen zur Beseitigung von Sebum. 5. Use of isobutyramides according to claim 1 or 2 or of preparations according to claim 3 for the prophylaxis and treatment of to reduce the production of sebum or the use of cyclodextrins for the production of preparations for eliminating sebum.
6. Verwendung nach Anspruch 5 zur Verhinderung der Bildung von Comedonen und/oder Akne. 6. Use according to claim 5 for preventing the formation of comedones and/or acne.
7. Verwendung nach Anspruch 5 zur Verhinderung oder Beseitigung von seborrhoischen Erscheinungen, insbesondere fettiges Haar, aber auch Kopfschup- pen.
7. Use according to claim 5 for preventing or eliminating seborrheic phenomena, in particular greasy hair, but also dandruff.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020210535.9A DE102020210535A1 (en) | 2020-08-19 | 2020-08-19 | New isobutyramide derivatives, cosmetic and/or dermatological preparations containing such compounds and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions |
PCT/EP2021/071523 WO2022037927A1 (en) | 2020-08-19 | 2021-08-02 | New isobutyryamide derivatives, cosmetic and/or dermatological preparations containing said compounds, and their use for the prophylaxis and treatment of sensible, in particular inflamed skin or inflammatory skin conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4200285A1 true EP4200285A1 (en) | 2023-06-28 |
Family
ID=77543471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21762623.3A Pending EP4200285A1 (en) | 2020-08-19 | 2021-08-02 | New isobutyryamide derivatives, cosmetic and/or dermatological preparations containing said compounds, and their use for the prophylaxis and treatment of sensible, in particular inflamed skin or inflammatory skin conditions |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230312495A1 (en) |
EP (1) | EP4200285A1 (en) |
CN (1) | CN116096346A (en) |
BR (1) | BR112023003093A2 (en) |
DE (1) | DE102020210535A1 (en) |
WO (1) | WO2022037927A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116554122B (en) * | 2023-06-29 | 2023-09-19 | 南京桦冠生物技术有限公司 | Alpha-keto acid amide or substituted oxalic acid amide ester compound and composition thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011083259A1 (en) | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Alkylamidothiazoles, their cosmetic or dermatological use and cosmetic or dermatological preparations containing such Alkylamidothiazolen |
DE102013226711A1 (en) * | 2013-12-19 | 2015-06-25 | Beiersdorf Ag | Use of alkylamidothiazoles in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin |
-
2020
- 2020-08-19 DE DE102020210535.9A patent/DE102020210535A1/en not_active Withdrawn
-
2021
- 2021-08-02 WO PCT/EP2021/071523 patent/WO2022037927A1/en unknown
- 2021-08-02 BR BR112023003093A patent/BR112023003093A2/en unknown
- 2021-08-02 EP EP21762623.3A patent/EP4200285A1/en active Pending
- 2021-08-02 CN CN202180055944.7A patent/CN116096346A/en active Pending
- 2021-08-02 US US18/041,742 patent/US20230312495A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022037927A1 (en) | 2022-02-24 |
DE102020210535A1 (en) | 2022-03-24 |
BR112023003093A2 (en) | 2023-03-28 |
US20230312495A1 (en) | 2023-10-05 |
CN116096346A (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60313597T2 (en) | TOPICAL PHARMACEUTICAL COMPOSITIONS WITH PROANTHOCYANIDINES, GLYCYRRHETINIC ACID AND TELEMINE TESTS FOR THE TREATMENT OF DERMATITIS | |
EP0847279B1 (en) | Antipruriginous cosmetic and/or pharmaceutical compositions consisting of one or several light local anaesthetics and one or several astringent substances | |
EP3082752B1 (en) | Use of alkylamidothiazoles in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin | |
EP0687467A2 (en) | Cosmetic and dermatological combinations containing glycerylalkylethers as active ingredients | |
DE69916695T2 (en) | Use of at least one hydroxystilbene as an agent for reducing the adhesion of microorganisms | |
EP1172084A2 (en) | Cosmetic and dermatologic composition to eliminate sebum | |
DE10025124B4 (en) | Combinations of glycerol monoalkyl ethers and aryl-substituted alcohols | |
EP1179338A1 (en) | Cosmetic and dermatological compositions comprising cyclodextrines for removing sebum | |
EP4200285A1 (en) | New isobutyryamide derivatives, cosmetic and/or dermatological preparations containing said compounds, and their use for the prophylaxis and treatment of sensible, in particular inflamed skin or inflammatory skin conditions | |
DE19615575A1 (en) | Use of glucosides and ferulic acid as an anti-irritative agent in cosmetic and topical dermatological preparations | |
DE102005008299A1 (en) | Cosmetic and/or dermatological formulation, useful as e.g. antiseptic, comprises metallic silver as active agent, auxiliary- and basic- materials | |
EP2711050A1 (en) | Compound and cosmetic preparation with such a compound | |
WO2009115216A1 (en) | Use of a component or extract from the baobab plant for skin diseases | |
WO2005030157A1 (en) | Cosmetic or dermatological preparations having a content of isoflavones and licochalcone a | |
WO2002076409A2 (en) | Cosmetic and dermatological preparations comprising an isoflavone content | |
EP2560666A1 (en) | Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate) | |
EP1834631B1 (en) | Cosmetic or dermatological preparations containing glycyrrhetin and/or glycyrrhizin and glucose derivatives or glycerin ethers | |
EP0620000A3 (en) | Cosmetic or pharmaceutical use of N-acylalcanolamines | |
WO2002076410A2 (en) | Cosmetic and dermatological preparations comprising a content of a hop extract or hop-malt extract | |
DE19615578A1 (en) | Use of Salix nigra extract as an anti-irritant agent in cosmetic and topical dermatological preparations | |
EP2076240B1 (en) | Cosmetic or dermatological preparations with a content of 2-isopropyl-5- methyl-cyclohexanecarbonyl-d-alanine methyl ester annd one or more anti-inflammatory agents | |
DE19832889A1 (en) | Process for the isolation and purification of fatty acids and hydroxy fatty acids from insect waxes and their use | |
WO2023151898A1 (en) | Tofa analogues, sebum reduction preparations containing said type of analogues and the cosmetic and/or therapeutic use of said type of analogues as an effective principle for reducing or preventing sebum | |
WO2018099675A1 (en) | Use of 2'-methoxyflavone in cosmetic or dermatological preparations for the prevention and treatment of sensitive skin | |
DE102012218116A1 (en) | Use of ingredients of extracts from seeds of jackfruit tree (Artocarpus heterophyllus) in cosmetic or dermatological preparations for prophylaxis the treatment of e.g. sensitive skin, itching and dry skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230420 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEIERSDORF AG |